TNFRSF9 and neoplasm: Another trial evaluated combining the anti-PD-1 antibody pembrolizumab with CB307, a bispecific antibody targeting PSMA on tumor cells and the 4-1BB co-stimulatory receptor on T-cells (designed to provide tumor-localized 4-1BB agonism), to augment T-cell cytotoxic activity [87].